PDCD1 and melanoma: A multicenter study involving 538 melanoma patients treated with pembrolizumab revealed that for every 10‐year increase in age, the risk of disease progression decreased by 13%, with patients over 60 years of age demonstrating higher efficacy with anti‐PD‐1 therapy.[57] The clinical outcomes are consistent with the trait.